UNICREDIT BANK/CALL/BIOGEN IDEC/400/0.1/14.01.26 | Market Closed - BOERSE MUENCHEN 01:10:10 26/06/2024 am IST | ||
| 1.01 EUR | -6.48% |
|
| Current month | -12.17% | ||
| 1 month | -4.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 1.01 | -6.48% |
| 24/24/24 | 1.08 | +4.85% |
| 21/24/21 | 1.03 | -2.83% |
| 20/24/20 | 1.06 | +1.92% |
| 19/24/19 | 1.04 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD28PH |
| ISIN | DE000HD28PH8 |
| Date issued | 29/01/2024 |
| Strike | 400 $ |
| Maturity | 14/01/2026 (568 Days) |
| Parity | 10 : 1 |
| Emission price | 1.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.65 € |
|---|---|
| Lowest since issue | 0.44 € |
| Spread | 0.07 € |
| Spread % | 6.73% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
223.2
USD
Average target price
283.2
USD
Spread / Average Target
+26.87%
- Stock Market
- Warrants
- Warrant
